Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
866 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07435038 | Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | recruiting | Phase 1 / Phase 2 | 120 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 2 | Sep 18, 2026 | clinicaltrials |
| NCT07667842 | Study of D3L-002 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 | 24 | D3 Bio (Wuxi) Co., LtdINDUSTRY | 2 | Sep 18, 2026 | clinicaltrials |
| NCT03486873 |
| Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) |
| recruiting |
| Phase 3 |
| 3,500 |
| Merck Sharp & Dohme LLCINDUSTRY |
| 51 |
| Sep 17, 2026 |
| clinicaltrials |
| NCT04293562 | A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations | recruiting | Phase 3 | 1,400 | Children's Oncology GroupNETWORK | 4 | Sep 17, 2026 | clinicaltrials |
| NCT04889924 | ALND vs ART in Positive Sentinel Node After Neoadjuvant Therapy in Breast Cancer(ADARNAT) | recruiting | N/A | 820 | Hospital Universitari de BellvitgeOTHER | 2 | Sep 17, 2026 | clinicaltrials |
| NCT04910568 | A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma(CAMMA 1) | recruiting | Phase 1 | 186 | Genentech, Inc.INDUSTRY | 13 | Sep 17, 2026 | clinicaltrials |
| NCT06340568 | A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer(Fern-EC-01) | recruiting | Phase 3 | 480 | BioNTech SEINDUSTRY | 26 | Sep 17, 2026 | clinicaltrials |
| NCT06353386 | Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) | recruiting | Phase 1 / Phase 2 | 220 | Merck Sharp & Dohme LLCINDUSTRY | 20 | Sep 17, 2026 | clinicaltrials |
| NCT06395103 | Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) | recruiting | Phase 1 / Phase 2 | 90 | Merck Sharp & Dohme LLCINDUSTRY | 23 | Sep 17, 2026 | clinicaltrials |
| NCT06816927 | Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab(GIANT) | recruiting | Phase 2 | 92 | Duke UniversityOTHER | 2 | Sep 17, 2026 | clinicaltrials |
| NCT06863272 | A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) | recruiting | Phase 1 / Phase 2 | 360 | Merck Sharp & Dohme LLCINDUSTRY | 19 | Sep 17, 2026 | clinicaltrials |
| NCT06925737 | A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) | recruiting | Phase 3 | 1,440 | Merck Sharp & Dohme LLCINDUSTRY | 35 | Sep 17, 2026 | clinicaltrials |
| NCT06941272 | A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01) | recruiting | Phase 1 / Phase 2 | 50 | Merck Sharp & Dohme LLCINDUSTRY | 23 | Sep 17, 2026 | clinicaltrials |
| NCT06952504 | A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)(TroFuse-033) | recruiting | Phase 3 | 1,123 | Merck Sharp & Dohme LLCINDUSTRY | 34 | Sep 17, 2026 | clinicaltrials |
| NCT07173751 | ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer | recruiting | Phase 3 | 558 | BioNTech SEINDUSTRY | 17 | Sep 17, 2026 | clinicaltrials |
| NCT07195695 | Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations | recruiting | Phase 3 | 400 | Boehringer IngelheimINDUSTRY | 28 | Sep 17, 2026 | clinicaltrials |
| NCT07227415 | Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer | recruiting | Phase 1 / Phase 2 | 224 | PfizerINDUSTRY | 6 | Sep 17, 2026 | clinicaltrials |
| NCT07318558 | A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)(TroFuse-021) | recruiting | Phase 3 | 900 | Merck Sharp & Dohme LLCINDUSTRY | 29 | Sep 17, 2026 | clinicaltrials |
| NCT07365319 | A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.(TeLuRide-008) | recruiting | Phase 2 / Phase 3 | 750 | Eikon TherapeuticsINDUSTRY | 3 | Sep 17, 2026 | clinicaltrials |
| NCT07625644 | BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01) | recruiting | Phase 3 | 550 | SystImmune Inc.INDUSTRY | 14 | Sep 17, 2026 | clinicaltrials |
| NCT07639450 | N-3C01 Monotherapy and Combination With PD-(L)1 Inhibitors in Advanced Solid Tumors(Solid Tumors) | recruiting | Phase 1 / Phase 2 | 114 | Hefei Xinzhu Biological Technology Co., Ltd.INDUSTRY | 2 | Sep 17, 2026 | clinicaltrials |
| NCT07778316 | Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)(DeLLphi-315) | recruiting | Phase 3 | 400 | AmgenINDUSTRY | 5 | Sep 17, 2026 | clinicaltrials |
| NCT04065399 | A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation(AUGMENT-101) | recruiting | Phase 1 / Phase 2 | 447 | Syndax PharmaceuticalsINDUSTRY | 11 | Sep 16, 2026 | clinicaltrials |
| NCT04613596 | Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 | recruiting | Phase 2 / Phase 3 | 626 | Mirati Therapeutics Inc.INDUSTRY | 47 | Sep 16, 2026 | clinicaltrials |
| NCT05786924 | Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies | recruiting | Phase 1 / Phase 2 | 554 | Institut de Recherches Internationales ServierOTHER | 10 | Sep 16, 2026 | clinicaltrials |
| NCT06029270 | Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer | recruiting | Phase 2 | 156 | National Cancer Institute (NCI)NIH | 5 | Sep 16, 2026 | clinicaltrials |
| NCT06233942 | Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 308 | BeOne MedicinesINDUSTRY | 5 | Sep 16, 2026 | clinicaltrials |
| NCT06463587 | Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad) | recruiting | Phase 3 | 264 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyINDUSTRY | 25 | Sep 16, 2026 | clinicaltrials |
| NCT06585410 | Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma | recruiting | Phase 3 | 369 | Regeneron PharmaceuticalsINDUSTRY | 2 | Sep 16, 2026 | clinicaltrials |
| NCT06824168 | Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission | recruiting | Phase 2 | 130 | Daiichi SankyoINDUSTRY | 5 | Sep 16, 2026 | clinicaltrials |
| NCT07332455 | First-Time-in-Human Study of GSK5471713 in Adults With mCRPC | recruiting | Phase 1 / Phase 2 | 54 | GlaxoSmithKlineINDUSTRY | 8 | Sep 16, 2026 | clinicaltrials |
| NCT04073706 | Sentinel Node Biopsy in Endometrial Cancer(ENDO-3) | recruiting | Phase 3 | 760 | Queensland Centre for Gynaecological CancerOTHER_GOV | 7 | Sep 15, 2026 | clinicaltrials |
| NCT04585750 | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | recruiting | Phase 1 / Phase 2 | 300 | PMV Pharmaceuticals, IncINDUSTRY | 9 | Sep 15, 2026 | clinicaltrials |
| NCT04996875 | (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis | recruiting | Phase 2 | 140 | Cogent Biosciences, Inc.INDUSTRY | 14 | Sep 15, 2026 | clinicaltrials |
| NCT05410145 | A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation | recruiting | Phase 1 / Phase 2 | 442 | D3 Bio (Wuxi) Co., LtdINDUSTRY | 10 | Sep 15, 2026 | clinicaltrials |
| NCT06132438 | Immunotherapy Targeting of Cytomegalovirus Antigens in Glioblastoma | recruiting | Phase 1 | 26 | Charlotte LemechOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06423911 | Study of Olverembatinib (HQP1351) in Patients With CML-CP(POLARIS-2) | recruiting | Phase 3 | 333 | Ascentage Pharma Group Inc.INDUSTRY | 16 | Sep 15, 2026 | clinicaltrials |
| NCT06492616 | A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence(ELEGANT) | recruiting | Phase 3 | 4,220 | Stemline Therapeutics, Inc.INDUSTRY | 28 | Sep 15, 2026 | clinicaltrials |
| NCT06615479 | A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2) | recruiting | Phase 3 | 440 | Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyINDUSTRY | 31 | Sep 15, 2026 | clinicaltrials |
| NCT06976710 | PRIORITY-CONNECT 2 Trial(PC2) | recruiting | N/A | 564 | Surgical Outcomes Research Centre (SOuRCe)NETWORK | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07023627 | A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression(MAESTRA 1) | recruiting | Phase 2 | 160 | Incyte CorporationINDUSTRY | 8 | Sep 15, 2026 | clinicaltrials |
| NCT07195916 | A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies | recruiting | Phase 1 | 280 | Incyte CorporationINDUSTRY | 5 | Sep 15, 2026 | clinicaltrials |
| NCT07214779 | Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression(MAESTRA 2) | recruiting | Phase 3 | 466 | Incyte CorporationINDUSTRY | 16 | Sep 15, 2026 | clinicaltrials |
| NCT07284849 | A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer | recruiting | Phase 3 | 700 | Incyte CorporationINDUSTRY | 22 | Sep 15, 2026 | clinicaltrials |
| NCT07341737 | SL-28 for Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 60 | Second Life TherapeuticsINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07493512 | Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer | recruiting | Phase 1 | 40 | AmgenINDUSTRY | 2 | Sep 15, 2026 | clinicaltrials |
| NCT07630545 | A Phase I Study in Healthy Volunteers and Parkinson's Disease (PD) Patients. | recruiting | Phase 1 | 106 | Mission TherapeuticsNETWORK | 4 | Sep 15, 2026 | clinicaltrials |
| NCT04771130 | A Study of BGB-11417 in Participants With Myeloid Malignancies | recruiting | Phase 1 / Phase 2 | 260 | BeOne MedicinesINDUSTRY | 10 | Sep 14, 2026 | clinicaltrials |
Data updated 12 days agoSource updated unknownsource: clinicaltrials